Incontinentia pigmenti: report on data from 2000 to 2013 by Francesca Fusco et al.
Fusco et al. Orphanet Journal of Rare Diseases 2014, 9:93
http://www.ojrd.com/content/9/1/93LETTER TO THE EDITOR Open AccessIncontinentia pigmenti: report on data from 2000
to 2013
Francesca Fusco1*, Mariateresa Paciolla1,2, Matilde Immacolata Conte1, Alessandra Pescatore1, Elio Esposito1,
Peppino Mirabelli3, Maria Brigida Lioi2 and Matilde Valeria Ursini1,3Abstract
We report here on the building-up of a database of information related to 386 cases of Incontinentia Pigmenti
collected in a thirteen-year activity (2000–2013) at our centre of expertise. The database has been constructed on
the basis of a continuous collection of patients (27.6/year), the majority diagnosed as sporadic cases (75.6%). This
activity has generated a rich source of information for future research studies by integrating molecular/clinical data
with scientific knowledge. We describe the content, architecture and future utility of this collection of data on IP to
offer comprehensive anonymous information to the international scientific community.
Keywords: Incontinentia pigmenti, Genomic disorder, Neuroectodermal disorder, Molecular diagnosis, Registry,
DatabaseIntroduction
Incontinentia pigmenti (IP; OMIM#308300) is a rare mul-
tisystemic genomic disorder with an estimated prevalence
at birth of 0.7/100,000 [1]. IP is X-linked and usually lethal
in males, and affecting the skin, but also other neuroec-
todermal tissues, in females. The skin lesions are the first
clinical manifestations that appear, starting in the neonatal
period with a vesiculobullous eruption (Stage I) and fol-
lowing a three stage evolution varying in duration from
months to years, namely a verrucous stage (Stage II), a hy-
perpigmented stage (Stage III), and finally a hypopigmen-
ted stage (Stage IV) usually continuing throughout life
[2,3]. Such skin defects, that follows Blaschko lines, are al-
ways present in IP and are therefore considered the main
diagnostic criteria for IP according to Landy and Donnai
(1993) [2]. The severity of the disease is related to the
presence of neurological and/or ocular impairment [4].
Overall, the prevalence of functional Central Nervous Sys-
tem (CNS) manifestations is approximately 30% [5,6] ran-
ging from a single-seizure episode to severe motor and
intellectual disability [7]. Ophthalmologic abnormalities
are present in approximately 20%–37% of IP patients
[5,6,8]. IP is due to a mutation of the X-linked IKBKG/* Correspondence: francesca.fusco@igb.cnr.it
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unless otherwise stated.NEMO gene (Inhibitor of Kappa polypeptide gene enhan-
cer in B-cells, Kinase Gamma/Nuclear Factor κB, Essen-
tial Modulator, GenBank NM_003639.3, OMIM#300248).
Most cases have a recurrent deletion (IKBKGdel or
NEMOdel4-10), removing exons 4–10 of the IKBKG/
NEMO gene. Non recurrent genomic rearrangements in
the IP locus and point mutations in the IKBKG/NEMO
coding region have also been reported [9-11]. IKBKG/
NEMO encodes for NEMO/IKKγ a regulatory subunit of
the Inhibitor of the kappaB (IκB) Kinase (IKK) complex
required for the canonical NF-κB pathway activation
involved in many fundamental physiological and pa-
thological functions [12,13]. Most IP female patients
present with a skewed X-inactivation. The X-chromosome
linked IKBKG/NEMO mutation causes an unbalanced
X-inactivation in female IP patients [14], as in other
X-linked diseases [15,16], because the absence of the
NEMO/IKKγ protein makes the IP cells more sensitive to
apoptosis [9]. In males, the extensive apoptosis is respon-
sible for their early fetal lethality [17]. Occasionally, male
patients with IP have been reported. They have shown the
characteristic skin lesions observed in females and pre-
sented a postzygotic mosaicism for the IKBKG/NEMO
exons4-10 gene deletion [18]. IP has also been diagnosed
in males with a 47,XXY karyotype (Klinefelter syndrome)
[19]. The large heterogeneity of defects, the severe clinical
presentations, and the wide spectrum of IKBKG/NEMOtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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http://www.ojrd.com/content/9/1/93alterations [7,11,14,20] makes the selection of homo-
geneous groups of patients difficult, precluding any the-
rapeutic approaches. Indeed, despite the considerable
progress that has been made in detailing the basic path-
ology of the IP disorder, the gap between research and
clinical care has remained wide. Moreover, the paucity of
patients collected at each single diagnostic centre makes
an overall epidemiological report difficult. The integration
of scattered resources may be crucial for the success of fu-
ture scientific accomplishments.
Methods
Here, we report the setting up of a central data reposi-
tory relating to a cohort of IP patients, the data having
been collected in a 13-year-long experience (2000–2013)
at our Italian centre of expertise for the molecular diag-
nosis of IP [21]. The IP patients included in our study
have been selected on the basis of the Landy and Donnai
(1993) [2] diagnostic criteria, and they also meet the most
recently updated IP criteria [22]. We have constructed the
first platform for the integration of molecular and clinical
data on IP patients. Our sample comprises 386 patients
(261 from Italian, 105 from European and 20 from non-
European clinical centers), with an annual average of 27.6
new cases of IP diagnosed per year (Figure 1).
All the clinical information has been obtained for
each patient through their completion of a clinical IP
questionnaire developed by the Incontinentia Pigmenti
International Foundation (IPIF, [http://www.ipif.org/
ip_consortium.html], further extended by the France
Incontinentia Pigmenti association (FIP, [http://incon
tinentia-pigmenti.fr/]) and by the Italian ASSociation of
Incontinentia Pigmenti (IPASSI, [http://www.incontinen
tiapigmenti.it/]). A clinical IP questionnaire is available
upon request from these organizations. We have integrated
the clinical data with molecular diagnosis results for the
IKBKG/NEMO alteration, by way of a well-standardized
protocol [10,14,23]. The technical development of theFigure 1 Annual distribution of the IP samples that have been receivregister has involved significant preparatory work consist-
ing in the building up of an in-house electronic database
which is comprehensive and permissive, and which has a
flexible structure able to register in an anonymous form
the pool data from the patients. We have assigned one rec-
ord to each IP sample, registered with a pseudonymous
code. Each record has three domains: the pedigree, the
clinical and the genetic domain. The Web domain will be
available at link [http://www.igb.cnr.it/ipgb]. The data are
not accessible to everyone but only to authorized users
through the use of a protected password. A data-mining
interface has been developed to ensure maximum flexibil-
ity so that users can perform any search they want using
the “search” button placed in the homepage after the “log
in”. It is possible to perform multiple searches at once. To
make the database permissive and flexible the first page
contains only the three domains set.
Results
The pedigree and clinical information are available for
308 IP cases, while the genetic data are available for 193
samples, respectively (Table 1). The pedigree domain con-
tains more detailed entries accommodating the family
data, for example the presence of an IP mother, sister, or
grandmother, indicating the inheritance of the disease. We
have registered 233 sporadic cases (75.6%) and 72 familial
cases (23.4%) in our IP cohort.
The clinical domain consists of seven clinical items,
one for each aspect of the phenotype presentation: “Skin
defects”, “CNS defects”, “Ophthalmologic defects”, “Teeth
defects”, “Hair defects”, “Fingernail defects” and “Develop-
mental evolution”. A drop-down menu has been assigned
to each item that, in most cases, contains details about all
the specific alterations affecting the tissue, and, in
addition, an open space for the annotation of novel clinical
features. For example, the item “Skin defects” contains a
drop-down menu indicating the stage of the IP skin ab-
normality, the age of onset, the type of alteration, and theed by the IGB centre for molecular diagnosis.
Table 1 IP data registry
Number of cases Percentage of cases
Database information 386 records
IP female samples 349 90.4
IP male samples 37 9.6
Pedigree domain 308 available
Sporadic cases 233 75.6
Familial cases 72 23.4
Clinical domain* 308 available
Skin defects 308 100
CNS defects 97 31.5
Ophthalmologic defects 94 30.5
Teeth defects 134 43.5
Hair defects 82 26.6
Fingernail defects 45 14.6
Developmental evolution 30 9.7
Genetic domain 193 available
NEMOdel4-10 145 75.1
IKBKG/NEMO point mutation 32 22.1
IP locus rearrangement 7 3.6
No known alteration found 9 4.7
*IP patients can have more than one defect affecting different organ systems.
Table 3 IP clinical data






Mental retardation 29 29.9
Spastic paresis 16 16.5
Cerebral atrophy 13 13.4
Microcephaly 11 11.3
Hydrocephaly 5 5.1
Ischemic strokes* 5 5.1
White matter alterations* 4 4.1
Arachnoid cysts* 3 3.1
Cortico-subcortical atrophy* 3 3.1
Brain morphological alterations* 2 2.1
Teeth defects 134
Delayed primary dentition 46 34.3
Cone/peg shaped teeth 30 22.3
Delayed permanent dentition 30 22.3
Teeth dystrophy 23 17.2
Impactions 23 17.2
Ophthalmologic defects 94
Vision defects 16 17
Retinopathy 15 15.9
Retinal detachment 8 8.5
Microphthalmia 6 6.4
Retinal neuropathy 6 6.4





Nail dystrophy 29 64
Developmental evolution 30
Recurrent infections 36 11.7
Syndactyly of fingers or toes 4 1.3
*Data obtained by Magnetic Resonance Imaging analysis in 17 IP cases.
**IP patients can have more than one defect affecting different organ systems.
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report that the most frequent first symptoms leading to
diagnosis, typically skin alterations (Stage I), appear before
the first year in 99% of cases. The second stage and the
third stage are reported within the first year in 96.6% and
in 82.8% of cases, respectively. After this date the fourth
stage is generally present (Table 2). The specific frequency
of each IP specific neuroectodermal defect observed in
our cohort is shown in Table 1. CNS abnormalities were
present in 31.5% (Table 1). In 17 cases, these were diag-
nosed by magnetic resonance imaging (Table 3).
The genetic domain of the database contains four items:
“NEMOdel4-10”, “IKBKG/NEMO point mutation”, “IP
locus rearrangement”, and “No known alteration found”
(Table 1). The mutation names comply with the accepted
guidelines proposed by the Human Genome Variation So-
ciety [www.hgvs.org/mutnomen] [24]. The genetic domain
reveals that 75.1% of patients have the NEMOdel4-10
deletion, 22.1% have an IKBKG/NEMO point mutation,Table 2 IP skin clinical data
Skin alteration age of onset
Skin defects IP cases <1° month 1° month-1° year >1° year
Stage I 183 160(87.4%) 21(11.5%) 2(1.1%)
Stage II 90 38(42.2%) 49(54.4%) 3(3.3%)
Stage III 87 18(27.6%) 58(55.2%) 11(17.1%)
Stage IV 81 0 0 81(100%)3.6% have an extended deletion in the IKBKG/NEMO
locus, and 4.7% have no known alteration in the IP locus
(Table 1).
Finally, in each domain (pedigree, clinical, and genetic)
an additional item, named “Supplementary Information”,
records in the database any supplementary data from
the patient and his/her family when these are available
(examples: presence of miscarriages; presence of non-
pathogenic alterations in IP locus [25] such as deletions
or point mutations in the NEMO pseudogene).
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The building up of this database represents the first de-
tailed integrated clinical/molecular diagnostic platform
on IP patients, the largest collection of an IP cohort in
Italy and to the best of our knowledge the first presented
to the scientific community worldwide. Thus, this phe-
notype and genotype database related to IP acts as a
unique attempt to improve patient care and healthcare
planning since it collects together information that would
otherwise be scattered. Finally, we strongly believe that
the use of the database is a powerful tool to facilitate
the selection of biological samples and/or the enrol-
ment of patients for the organization of appropriate cli-
nical trials. Physicians wishing to include patients in the
IP database may contact the Authors: Francesca Fusco
and/or Matilde Valeria Ursini by email (incontinentia.
pigmenti@igb.cnr.it).
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